STOCK TITAN

[Form 4] Neuropace, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

NeuroPace CFO Patrick F. Williams received significant equity compensation on June 20, 2025, consisting of two main components:

Restricted Stock Units (RSUs):

  • 51,850 RSUs granted at $0 cost
  • Vesting schedule: 25% vests on June 20, 2026, remaining vests quarterly over 3 years

Stock Options:

  • 87,950 options granted with strike price of $10.41
  • 10-year term, expiring June 19, 2035
  • Same vesting schedule as RSUs: 25% after one year, then quarterly over 3 years

This compensation package demonstrates NeuroPace's strategy to align executive interests with long-term shareholder value through equity incentives with extended vesting periods.

Il CFO di NeuroPace, Patrick F. Williams, ha ricevuto una significativa remunerazione in azioni il 20 giugno 2025, composta da due componenti principali:

Azioni Vincolate (RSU):

  • 51.850 RSU con costo pari a $0
  • Programma di maturazione: il 25% matura il 20 giugno 2026, il resto matura trimestralmente nei successivi 3 anni

Opzioni su Azioni:

  • 87.950 opzioni con prezzo di esercizio di $10,41
  • Durata di 10 anni, scadenza il 19 giugno 2035
  • Stesso programma di maturazione delle RSU: 25% dopo un anno, poi trimestralmente per 3 anni

Questo pacchetto retributivo riflette la strategia di NeuroPace di allineare gli interessi dei dirigenti al valore a lungo termine per gli azionisti, attraverso incentivi azionari con periodi di maturazione estesi.

El CFO de NeuroPace, Patrick F. Williams, recibió una compensación significativa en acciones el 20 de junio de 2025, que consta de dos componentes principales:

Unidades de Acciones Restringidas (RSU):

  • 51,850 RSU otorgadas sin costo
  • Calendario de adquisición: 25% se adquiere el 20 de junio de 2026, el resto se adquiere trimestralmente durante 3 años

Opciones sobre Acciones:

  • 87,950 opciones con precio de ejercicio de $10.41
  • Plazo de 10 años, expiran el 19 de junio de 2035
  • Mismo calendario de adquisición que las RSU: 25% después de un año, luego trimestralmente durante 3 años

Este paquete de compensación demuestra la estrategia de NeuroPace de alinear los intereses ejecutivos con el valor a largo plazo para los accionistas mediante incentivos accionarios con períodos de adquisición prolongados.

NeuroPace의 CFO 패트릭 F. 윌리엄스는 2025년 6월 20일에 두 가지 주요 구성 요소로 이루어진 상당한 주식 보상을 받았습니다:

제한 주식 단위(RSUs):

  • 비용 $0로 51,850 RSU 부여
  • 베스팅 일정: 2026년 6월 20일에 25% 베스팅, 나머지는 3년 동안 분기별 베스팅

스톡 옵션:

  • 행사가격 $10.41로 87,950 옵션 부여
  • 10년 만기, 2035년 6월 19일 만료
  • RSU와 동일한 베스팅 일정: 1년 후 25%, 이후 3년간 분기별 베스팅

이 보상 패키지는 장기간 베스팅 기간을 가진 주식 인센티브를 통해 경영진의 이익과 장기 주주 가치를 일치시키려는 NeuroPace의 전략을 보여줍니다.

Le directeur financier de NeuroPace, Patrick F. Williams, a reçu une rémunération importante en actions le 20 juin 2025, composée de deux éléments principaux :

Unités d'actions restreintes (RSU) :

  • 51 850 RSU attribuées sans coût
  • Calendrier d'acquisition : 25 % acquis le 20 juin 2026, le reste acquis trimestriellement sur 3 ans

Options d'achat d'actions :

  • 87 950 options attribuées avec un prix d'exercice de 10,41 $
  • Durée de 10 ans, expiration le 19 juin 2035
  • Même calendrier d'acquisition que les RSU : 25 % après un an, puis trimestriellement sur 3 ans

Ce package de rémunération illustre la stratégie de NeuroPace visant à aligner les intérêts des dirigeants sur la valeur à long terme des actionnaires grâce à des incitations en actions avec des périodes d'acquisition prolongées.

NeuroPace CFO Patrick F. Williams erhielt am 20. Juni 2025 eine bedeutende Aktienvergütung, die aus zwei Hauptbestandteilen besteht:

Restricted Stock Units (RSUs):

  • 51.850 RSUs ohne Kosten zugewiesen
  • Vesting-Zeitplan: 25 % am 20. Juni 2026, der Rest wird über 3 Jahre vierteljährlich freigegeben

Aktienoptionen:

  • 87.950 Optionen mit einem Ausübungspreis von 10,41 $
  • 10-Jahres-Laufzeit, Ablauf am 19. Juni 2035
  • Gleicher Vesting-Zeitplan wie bei den RSUs: 25 % nach einem Jahr, danach vierteljährlich über 3 Jahre

Dieses Vergütungspaket zeigt NeuroPaces Strategie, die Interessen der Führungskräfte durch langfristige Aktienanreize mit verlängerten Vesting-Perioden an den langfristigen Wert für die Aktionäre auszurichten.

Positive
  • CFO Patrick Williams received significant equity compensation package: 51,850 RSUs and 87,950 stock options at $10.41 exercise price, demonstrating long-term retention strategy and alignment with shareholder interests
Negative
  • None.

Il CFO di NeuroPace, Patrick F. Williams, ha ricevuto una significativa remunerazione in azioni il 20 giugno 2025, composta da due componenti principali:

Azioni Vincolate (RSU):

  • 51.850 RSU con costo pari a $0
  • Programma di maturazione: il 25% matura il 20 giugno 2026, il resto matura trimestralmente nei successivi 3 anni

Opzioni su Azioni:

  • 87.950 opzioni con prezzo di esercizio di $10,41
  • Durata di 10 anni, scadenza il 19 giugno 2035
  • Stesso programma di maturazione delle RSU: 25% dopo un anno, poi trimestralmente per 3 anni

Questo pacchetto retributivo riflette la strategia di NeuroPace di allineare gli interessi dei dirigenti al valore a lungo termine per gli azionisti, attraverso incentivi azionari con periodi di maturazione estesi.

El CFO de NeuroPace, Patrick F. Williams, recibió una compensación significativa en acciones el 20 de junio de 2025, que consta de dos componentes principales:

Unidades de Acciones Restringidas (RSU):

  • 51,850 RSU otorgadas sin costo
  • Calendario de adquisición: 25% se adquiere el 20 de junio de 2026, el resto se adquiere trimestralmente durante 3 años

Opciones sobre Acciones:

  • 87,950 opciones con precio de ejercicio de $10.41
  • Plazo de 10 años, expiran el 19 de junio de 2035
  • Mismo calendario de adquisición que las RSU: 25% después de un año, luego trimestralmente durante 3 años

Este paquete de compensación demuestra la estrategia de NeuroPace de alinear los intereses ejecutivos con el valor a largo plazo para los accionistas mediante incentivos accionarios con períodos de adquisición prolongados.

NeuroPace의 CFO 패트릭 F. 윌리엄스는 2025년 6월 20일에 두 가지 주요 구성 요소로 이루어진 상당한 주식 보상을 받았습니다:

제한 주식 단위(RSUs):

  • 비용 $0로 51,850 RSU 부여
  • 베스팅 일정: 2026년 6월 20일에 25% 베스팅, 나머지는 3년 동안 분기별 베스팅

스톡 옵션:

  • 행사가격 $10.41로 87,950 옵션 부여
  • 10년 만기, 2035년 6월 19일 만료
  • RSU와 동일한 베스팅 일정: 1년 후 25%, 이후 3년간 분기별 베스팅

이 보상 패키지는 장기간 베스팅 기간을 가진 주식 인센티브를 통해 경영진의 이익과 장기 주주 가치를 일치시키려는 NeuroPace의 전략을 보여줍니다.

Le directeur financier de NeuroPace, Patrick F. Williams, a reçu une rémunération importante en actions le 20 juin 2025, composée de deux éléments principaux :

Unités d'actions restreintes (RSU) :

  • 51 850 RSU attribuées sans coût
  • Calendrier d'acquisition : 25 % acquis le 20 juin 2026, le reste acquis trimestriellement sur 3 ans

Options d'achat d'actions :

  • 87 950 options attribuées avec un prix d'exercice de 10,41 $
  • Durée de 10 ans, expiration le 19 juin 2035
  • Même calendrier d'acquisition que les RSU : 25 % après un an, puis trimestriellement sur 3 ans

Ce package de rémunération illustre la stratégie de NeuroPace visant à aligner les intérêts des dirigeants sur la valeur à long terme des actionnaires grâce à des incitations en actions avec des périodes d'acquisition prolongées.

NeuroPace CFO Patrick F. Williams erhielt am 20. Juni 2025 eine bedeutende Aktienvergütung, die aus zwei Hauptbestandteilen besteht:

Restricted Stock Units (RSUs):

  • 51.850 RSUs ohne Kosten zugewiesen
  • Vesting-Zeitplan: 25 % am 20. Juni 2026, der Rest wird über 3 Jahre vierteljährlich freigegeben

Aktienoptionen:

  • 87.950 Optionen mit einem Ausübungspreis von 10,41 $
  • 10-Jahres-Laufzeit, Ablauf am 19. Juni 2035
  • Gleicher Vesting-Zeitplan wie bei den RSUs: 25 % nach einem Jahr, danach vierteljährlich über 3 Jahre

Dieses Vergütungspaket zeigt NeuroPaces Strategie, die Interessen der Führungskräfte durch langfristige Aktienanreize mit verlängerten Vesting-Perioden an den langfristigen Wert für die Aktionäre auszurichten.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Williams Patrick F.

(Last) (First) (Middle)
C/O NEUROPACE, INC.
455 N. BERNARDO AVENUE

(Street)
MOUNTAIN VIEW CA 94043

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
NeuroPace Inc [ NPCE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/20/2025 A 51,850(1) A $0 51,850 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $10.41 06/20/2025 A 87,950 (2) 06/19/2035 Common Stock 87,950 $0 87,950 D
Explanation of Responses:
1. Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 25% of the RSUs vest on June 20, 2026 and the remaining RSUs vest in twelve (12) equal quarterly installments thereafter.
2. 25% of the shares subject to the option vest on June 20, 2026. The remaining shares subject to the option vest in twelve (12) equal quarterly installments thereafter.
/s/ Leah Akin, Attorney-in-Fact 06/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options did NPCE's CFO Patrick Williams receive on June 20, 2025?

NPCE's CFO Patrick Williams received stock options to purchase 87,950 shares of common stock at an exercise price of $10.41 per share. The options begin vesting on June 20, 2026 with 25% of shares, followed by twelve equal quarterly installments. The options expire on June 19, 2035.

How many restricted stock units (RSUs) were granted to NPCE's CFO in June 2025?

Patrick Williams, NPCE's CFO, was granted 51,850 restricted stock units (RSUs) on June 20, 2025. The RSUs vest 25% on June 20, 2026, with the remaining RSUs vesting in twelve equal quarterly installments thereafter.

What is the vesting schedule for NPCE CFO's June 2025 equity grants?

Both the stock options and RSUs granted to NPCE's CFO follow the same vesting schedule: 25% vests on June 20, 2026 (the first anniversary), and the remaining 75% vests in twelve equal quarterly installments thereafter.

What was the total value of NPCE CFO Patrick Williams' June 2025 equity compensation?

The Form 4 shows Patrick Williams received 51,850 RSUs and 87,950 stock options. The RSUs were granted at $0, while the stock options have an exercise price of $10.41 per share. The total market value would depend on NPCE's stock price at the time of grant, which is not disclosed in this filing.
Neuropace Inc

NASDAQ:NPCE

NPCE Rankings

NPCE Latest News

NPCE Latest SEC Filings

NPCE Stock Data

330.61M
24.06M
3.38%
61.73%
0.75%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
MOUNTAIN VIEW